CCO Oncology Podcast

Expert Insight on Key Data From SGO 2022 Informing Treatment for Endometrial, Ovarian, and Cervical Cancers

Episode Summary

In this podcast episode, listen to David Scott Miller, MD, FACOG, FACS, and Angeles Alvarez Secord, MD, MHSc, discuss key data for gynecologic cancers presented at the 2022 SGO annual meeting, including data for novel agents in ovarian and endometrial cancers, and practical insights on recent approvals for cervical cancer.

Episode Notes

In this episode, David Scott Miller, MD, FACOG, FACS, and Angeles Alvarez Secord, MD, MHSc, provide expert insights on key data presented at SGO 2022 for ovarian, endometrial, and cervical cancers regarding:

• Results from the prospective phase III PRIME study of an individualized dose for niraparib vs placebo maintenance in newly diagnosed advanced ovarian cancer
• Final OS analysis from phase III SOLO-3 evaluating olaparib vs physician’s choice of single-agent nonplatinum chemotherapy in gBRCAm platinum-sensitive relapsed ovarian cancer
• Results from the phase III SORAYA trial of mirvetuximab soravtansine, an FRα-targeting ADC with a potent tubulin-targeting maytansinoid (DM4) delivered to tumor cells, in patients with platinum-resistant ovarian cancer who had recurrence within 6 months after last platinum dose and had 1-3 prior treatments
• Results from the randomized, double-blind, placebo-controlled phase III trial of selinexor vs placebo as maintenance in patients with stage IV endometrial cancer who had a PR/CR on ≥12 weeks of first-line taxane/carboplatin
• The results from a cost-effectiveness analysis for the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer

Presenters:

David Scott Miller, MD, FACOG, FACS
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Director and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics & Gynecology
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Dallas, Texas 

Angeles Alvarez Secord, MD, MHSc 
Professor
Division of Gynecologic Oncology
Department of OB/GYN
Duke Cancer Institute
Duke University Health System
Durham, North Carolina 

Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.

Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries: 
https://bit.ly/38xuRBv